8 ドメイン MOC
肺がん中心領域:
- lung-cancer-treatment — 肺がん・胸部悪性腫瘍の薬物療法
- lung-cancer-biology — 肺がん固有の driver 機序・lung-specific 病態
がん横断領域:
- cancer-extracellular-vesicles — がんにおける細胞外小胞
- cancer-neutrophils — がん微小環境の好中球・myeloid 細胞
- cancer-brain-metastasis — 全がん種の脳転移
- cancer-biology — がん種非依存の横断的バイオロジー
- novel-cancer-modalities — ADC / CAR-T / BiTE / mRNA vaccine 等
非腫瘍領域:
- respiratory-diseases — 非腫瘍呼吸器疾患
ノードカテゴリ
- Entities/ — 固有名詞ノード (薬剤・遺伝子・試験・経路・細胞種・サイトカイン・手法)。480 ページ
Entities/Drugs/(71):- Targeted TKI: EGFR-TKI / ALK-TKI / ROS1-TKI / RET-inhibitor / KRAS-G12C-inhibitor / NTRK-inhibitor / MET-TKI / FGFR-inhibitor / SHP2-inhibitor
- BRAF-MEK: BRAF-MEK-inhibitor
- Bispecific / HER: EGFR-MET-bispecific / HER2-directed-therapy / HER3-directed-therapy
- IO checkpoint: PD-1-inhibitor / PD-L1-inhibitor / CTLA-4-inhibitor / TIGIT-inhibitor / LAG-3-inhibitor / Mogamulizumab (anti-CCR4 Treg depletion)
- Brain-active TKI / Bispecific: Tucatinib (HER2 CNS-active) / Ivonescimab (PD-1×VEGF bispecific)
- Novel modality: ADC / Datopotamab-deruxtecan (TROP2 ADC) / BiTE-bispecific / DLL3-targeted-therapy / CAR-T-therapy / TCR-T-therapy / TIL-therapy / mRNA-vaccine / Cancer-vaccine / cGAS-STING-agonist / KRAS-G12C-CRISPR-modality (Cas12a2 RNA-trigger 型)
- Antibody: anti-VEGF-antibody / anti-EGFR-antibody / anti-VEGFR2-antibody
- Chemotherapy: Platinum-chemotherapy / Pemetrexed / Taxane / Docetaxel / Etoposide / Gemcitabine / Vinorelbine / Irinotecan-Topotecan / Lurbinectedin
- Anti-angiogenic TKI: VEGFR-TKI
- DDR / epigenetic / cell cycle: PARP-inhibitor / CDK4-6-inhibitor / PI3K-AKT-mTOR-inhibitor / BCL-2-inhibitor / EZH2-inhibitor / HDAC-inhibitor / Aurora-kinase-inhibitor / BET-inhibitor / Hypomethylating-agent
- Supportive: Corticosteroid
Entities/Genes/(119):- NSCLC drivers: EGFR / ALK / KRAS / ROS1 / HER2 / MET / BRAF / RET / NTRK / FGFR1 / NKX2-1 / PIK3CA / NRG1 / ERBB3 / IGF1R
- Tumor suppressor / co-mutation: TP53 / RB1 / STK11 / KEAP1 / CDKN2A / PTEN / NF1 / MDM2
- SCLC subtype TF / oncogene: ASCL1 / NEUROD1 / POU2F3 / MYC / MYCN / DLL3 / SOX2 / BCL2
- Chromatin / epigenetic: SMARCA4 / ARID1A / EZH2 / SETD2 / CREBBP / TET2
- DDR: ATM / BRCA1 / BRCA2 / SLFN11
- Signaling TF / kinase: STAT3 / JAK1 / AXL / NOTCH1 / CTNNB1 / NFE2L2 / TGFB1 / AKT1
- Immune / TME: PD-L1 / FOXP3 / B2M / CDH1 / KIT / SPP1 / LIF / TREM2 (myeloid checkpoint) / CXCR4 (CXCL12 receptor, metastasis organotropism)
- Mutagenesis / telomere: APOBEC3B / TERT
- Angiogenesis: VEGFA
- ADC target: TROP2 (TACSTD2)
- EV surface scaffold: TSPAN8 (tetraspanin, CSC-EV → CD103 binding)
Entities/Trials/(66):- EGFR: FLAURA / FLAURA2 / AURA3 / ADAURA / LAURA / IPASS / NEJ002 / WJTOG3405 / EURTAC / LUX-Lung-3 / LUX-Lung-7 / MARIPOSA / TATTON / SAVANNAH / PAPILLON (exon20ins)
- ALK: ALEX / CROWN / ALTA-1L / PROFILE-1014 / J-ALEX / ASCEND-4 / ALINA (adjuvant)
- ROS1 / HER2 / RET / KRAS / MET: CodeBreaK-200 / GEOMETRY-mono-1 / LIBRETTO-001 / LIBRETTO-431 / TRIDENT-1 (ROS1) / DESTINY-Lung02 (HER2 ADC)
- IO 1L: KEYNOTE-024 / KEYNOTE-189 / KEYNOTE-407 / KEYNOTE-042 / CheckMate-227 / CheckMate-9LA / IMpower150 / MYSTIC / HARMONi-2 (PD-1×VEGF bispecific)
- IO 2L: CheckMate-017 / CheckMate-057 / KEYNOTE-010 / OAK
- Anti-angiogenic: REVEL / LUME-Lung-1
- Stage III / 周術期 / adjuvant: PACIFIC / CheckMate-816 / KEYNOTE-671 / KEYNOTE-091 / LACE / JBR10 / AEGEAN
- SCLC: IMpower133 / CASPIAN / DeLLphi-301 / DeLLphi-304 / ADRIATIC / KEYNOTE-604
- Evolutionary biology: TRACERx
Entities/Pathways/(59):- Core signaling: MAPK-RAS-ERK-pathway / PI3K-AKT-mTOR-pathway / JAK-STAT-pathway / WNT-beta-catenin-pathway / TGF-beta-pathway / Hippo-YAP-pathway / Notch-pathway / HGF-MET-pathway / VEGF-angiogenesis-pathway
- RTK upstream: EGFR-signaling-pathway / ALK-ROS1-signaling-pathway / RAS-GTPase-cycle-pathway
- Innate immune sensing: cGAS-STING-pathway / NF-kB-pathway / Toll-like-receptor-pathway / Interferon-pathway / Complement-pathway / Neutrophil-recruitment-activation-pathway / cGAMP-intercellular-signaling-pathway
- Immune checkpoint / presentation: PD-1-PD-L1-signaling-pathway / CTLA-4-B7-signaling-pathway / Phagocytosis-checkpoint-pathway / MHC-I-antigen-processing-pathway / Antigen-presentation-pathway
- Neutrophil / chemokine axis: IL-8-CXCR1-CXCR2-pathway
- Cell death: Apoptosis-pathway / Ferroptosis-pathway / Necroptosis-pathway / Pyroptosis-inflammasome-pathway / Autophagy-pathway / Senescence-SASP-pathway
- Genome / epigenome / DNA repair: DDR-pathway / p53-pathway / Rb-E2F-cell-cycle-pathway / Epigenetic-chromatin-remodeling-pathway / Homologous-recombination-repair-pathway / Mismatch-repair-pathway
- Metabolism / vesicle / degradation: Metabolic-reprogramming-pathway / Sphingolipid-S1P-pathway / Exosome-biogenesis-pathway / Ubiquitin-proteasome-pathway / Oxidative-phosphorylation-pathway / Unfolded-protein-response-pathway / Itaconate-immunometabolism-pathway
- Tumor suppressor / co-mutation: AMPK-LKB1-pathway / NRF2-KEAP1-pathway / Hippo-Merlin-NF2-pathway
- Drug resistance bypass: Hippo-YAP-drug-resistance-pathway
- Bone / brain niche: RANK-RANKL-OPG-pathway / BBB-neurovascular-unit-pathway
- Morphogen: Hedgehog-pathway
Entities/CellTypes/(52):- Myeloid: Neutrophil-TAN / Macrophage-TAM / MDSC / Dendritic-cell / Eosinophil / Mast-cell / Monocyte / Tumor-associated-eosinophil
- Myeloid — DC subsets: cDC1 / cDC2 / Plasmacytoid-dendritic-cell
- Myeloid — Neutrophil subsets: Low-density-neutrophil / Aged-neutrophil
- Lymphoid: CD8-T-cell / CD4-T-helper-cell / Treg / NK-cell / Gamma-delta-T-cell / Invariant-NKT-cell / B-cell / ILC2 / ILC3
- Lymphoid — T cell subsets / states: Exhausted-CD8-T-cell / Tpex (TCF1+ progenitor exhausted, IO 応答 source) / Tfh-cell / Th17-cell / Th1-cell / Plasma-cell
- Engineered cell: CAR-T-cell
- Stromal / vascular: CAF / Endothelial-cell / Tumor-endothelial-cell / Pericyte / Mesenchymal-stem-cell
- Organ niche — Brain: Astrocyte / Reactive-astrocyte / Microglia / Border-associated-macrophage / Choroid-plexus-epithelial-cell
- Organ niche — Liver / Bone: Kupffer-cell / Hepatic-stellate-cell / Osteoclast / Osteoblast
- Blood: Platelet
- Lung-specific: Alveolar-epithelial-cell / AT2-cell / Club-cell / Neuroendocrine-cell
- Tumor cell state: Cancer-stem-cell / Drug-tolerant-persister / Circulating-tumor-cell
Entities/Cytokines/(55):- Pro-inflammatory cytokine: IL-6 / IL-1-beta / IL-1-alpha / TNF-alpha / IL-17A / IL-12 / IL-18 / IL-23 / IL-33 / HMGB1 / IL-32
- IFN family: IFN-gamma / IFN-alpha / IFN-beta / IFN-lambda
- Immunosuppressive / regulatory: IL-10 / TGF-beta / IL-4 / IL-35 / PGE2 / MIF
- T cell / NK stimulatory: IL-2 / IL-15 / IL-21 / Granzyme-B / Perforin / TRAIL
- Hematopoietic / colony-stimulating: GM-CSF / G-CSF / M-CSF
- IL-6 family: IL-6-family
- Epithelial / mucosal: IL-22
- Growth factor: VEGF
- Chemokine: IL-8 / CCL2 / CCL3 / CCL5 / CCL20 / CCL22 / CXCL1 / CXCL2 / CXCL5 / CXCL12 / CXCL13 / CXCL9-10-11
- Alarmin / DAMP: S100A8-A9
- Immune checkpoint ligand / costimulatory: Galectin-9 / OX40L / FasL
- Neutrophil effector: Neutrophil-elastase / Arginase-1
Entities/Methods/(58):- Single-cell / spatial omics: scRNA-seq / Spatial-transcriptomics / Multiome / ATAC-seq / scATAC-seq / CITE-seq / TCR-seq / CODEX-PhenoCycler / GeoMx-DSP
- Bulk omics: Bulk-RNA-seq / WES-WGS / ChIP-seq / Cut-and-Tag / Methylation-profiling / Proteomics-mass-spec / NGS-panel / Nanopore-long-read / Long-read-RNA-seq / Hi-C-3D-genome
- Liquid biopsy / PCR: ctDNA-liquid-biopsy / ddPCR
- Imaging: FISH / In-situ-hybridization / Multiplex-IF-imaging / IMC / Digital-pathology / Foundation-model-pathology / Tissue-clearing-3D-imaging / Radiomics
- Flow / mass cytometry: Flow-cytometry-CyTOF / ELISpot-functional-T-cell-assay
- Structural / interactome: Cryo-EM / Proximity-labeling-BioID-APEX
- Metabolomics: Metabolomics-LC-MS
- Extracellular vesicles: EV-isolation-characterization / EV-proteomics-cargo-analysis
- Functional perturbation: CRISPR-screen / Lineage-tracing / Base-editing / Prime-editing
- Model system: PDX / Organoid / GEMM / Syngeneic-model / Humanized-mouse / Patient-derived-tumor-fragment / Microfluidic-organ-on-chip
- Delivery: Nanoparticle-LNP
- Clinical / computational: Clinical-trial-design / Bayesian-adaptive-trial-design / Basket-umbrella-platform-trial / Real-world-data-analysis / Mendelian-randomization / Machine-learning-AI
- Concepts/ — 横断メカニズム・現象 (95 concept)
- Hallmarks of cancer: Hallmarks-of-cancer (Hanahan 2000→2011→2022→2026 進化) / Avoiding-immune-destruction / Genomic-instability-cancer / Tumor-promoting-inflammation
- Resistance paradigms: EGFR-T790M-resistance / EGFR-C797S-resistance / ALK-G1202R-compound-mutations / Compound-mutation-resistance / IO-primary-resistance / IO-acquired-resistance / ADC-resistance-mechanisms / Epigenetic-therapy-resistance / T-cell-exhaustion (Tex hierarchy: Tpex → Tex-int → Tex-term)
- Co-mutation / synthetic lethality: KRAS-co-mutation-landscape / Synthetic-lethality
- Driver paradigms: Oncogene-addiction / Tumor-mutational-burden / Clonal-evolution-ITH / Chromothripsis-ecDNA
- Lineage / plasticity: Lineage-plasticity / EMT / SCLC-molecular-subtypes / Phenotypic-plasticity-in-cancer
- Cell death / metabolism: Immunogenic-cell-death / Ferroptosis-cancer / Metabolic-reprogramming
- Metastasis / niche: Pre-metastatic-niche / NETosis-cancer-metastasis / Neutrophil-extracellular-traps / Cancer-dormancy / Bone-metastasis-vicious-cycle
- Brain metastasis: Brain-metastasis-immune-microenvironment / BBB-disruption-in-brain-metastasis / Leptomeningeal-metastasis / CNS-active-TKI-sequencing / SRS-ICI-radiation-necrosis / Brain-metastasis-clonal-evolution / Reactive-astrocyte-tumor-crosstalk / Brain-met-pre-metastatic-niche
- TME / immune: irAE-pathophysiology / Tertiary-lymphoid-structure / Tumor-immune-microenvironment-classification / Immune-checkpoint-beyond-PD1 / Tumor-stroma-interaction / Microbiome-cancer-immunity / Peritumor-microenvironment (CAF↔nerve↔immune triangle) / Tissue-resident-NK-antitumor (CD39+CD49a+CD103+ ctrNK) / NK-cell-therapy (allogeneic CAR-NK / cytokine-primed NK)
- Vasculature: Tumor-angiogenesis / Vascular-normalization
- Clinical paradigms: Perioperative-IO / Oligometastatic-disease / Abscopal-effect / MRD-ctDNA-monitoring / Liquid-biopsy-paradigm / Neutrophil-to-lymphocyte-ratio / Cancer-associated-thrombosis
- Neutrophil biology: Emergency-granulopoiesis / Neutrophil-heterogeneity-plasticity / Neutrophil-T-cell-suppression / Granulocytic-MDSC-vs-TAN / Neutrophil-EV-cargo-function / Neutrophil-IO-biomarker / NETosis-thrombosis-axis
- EV biology: EV-mediated-intercellular-communication / Exosomal-PD-L1 / EV-organotropism / Tumor-derived-EV-cargo-biology / EV-surface-ligand-signaling (cargo → surface ligand paradigm shift)
- Emerging fields / technology: Cancer-neuroscience / Spatial-transcriptomics-in-cancer
- Environmental exposome: PM2.5-lung-carcinogenesis (PM2.5 → IL-1β → EGFR-driven LCINS promoter paradigm)
合成済みアウトプット (Outputs/)
- hpcs-plasticity-hub-preemptive-targeting-translation — 2026-06-27 — Slc4a11+ HPCS など肺癌可塑性ハブの先制標的化は臨床へどこまで翻訳できるか
- antigen-presenting-tan-endogenous-t-cell-response — 2026-06-27 — 抗原提示性 TAN (HLA-DR+) の内因性 T 細胞応答寄与と SOX2-FADS1/PGE2 抑制解除
- car-cell-tme-resilience-engineering — 2026-06-27 — CAR 細胞の TME レジリエンス工学 (NR3C1 欠失・lymphodepletion 非依存 armored) で持続性・記憶を発揮できるか
- immunosuppressive-niche-single-target-phase1 — 2026-06-13 — 非リンパ系免疫抑制ニッチ (CD300ld-PS / CCL3-CCR1 / CHI3L1 / vascular STING) のどの単一標的から第 I 相 + 抗 PD-1 上乗せへ進めるか
- tumor-neuro-crosstalk-therapeutic-targeting — 2026-06-13 — 腫瘍-神経クロストーク (sensory-sympathetic / CGRP-RAMP1 / 神経シナプス) の治療標的化と β遮断薬・除神経 re-purposing の臨床検証可否
- pmn-ml-signature-liquid-biopsy-prediction — 2026-06-13 — EV/NET/老化好中球が駆動する pre-metastatic niche の ML signature 予測を多施設前向き検証 + CTC/ctDNA 付加価値証明へ橋渡し
- lineage-plasticity-pharmacological-lock — 2026-06-06 — Lineage plasticity を ‘lock’ する 5 vector (epigenetic / EMT-TF PROTAC / ZEB1+ ferroptosis / HPCS 細胞除去 / SCLC transformation 予防) の現状整理
- bbb-permeability-prediction-imaging-liquid-biopsy — 2026-06-06 — 脳転移 BBB/BTB 透過性の症例別予測 — 画像・liquid biopsy biomarker と cancer neuroscience integration (2026 update)
- novel-modality-sequencing-driver-resistance — 2026-06-06 — Bispecific / ADC / cell therapy の sequencing 戦略 — Driver-positive NSCLC 耐性後の novel modality 最適順序
- egfr-uncommon-mutation-treatment-selection — 2026-05-30 — EGFR uncommon 変異 (G719X/S768I/L861Q/exon20 ins/A763_Y764insFQEA/de novo T790M/複合) の variant 別治療選択
- alk-g1202r-compound-mutation-sequencing — 2026-05-30 — ALK G1202R 後 compound mutation の分子動態と 4th-gen TKI (NVL-655/TPX-0131) + sequencing 戦略
- net-targeting-anti-metastatic-benefit-risk — 2026-05-30 — DNase I/PAD4/NE 阻害の anti-metastatic 効果と phase II/III 設計の benefit-risk
- bbb-permeability-cns-drug-selection — 2026-05-30 — BBB/BTB 透過性の 4 階層と症例ベース薬剤選択 algorithm (Driver/病態/部位/既治療)
- kras-g12c-crispr-modality-synthesis — 2026-05-23 — KRAS G12C CRISPR-Cas12a2 modality (Scholz 2026) の第三 CRISPR axis 位置づけ・耐性株 51% 除去・LNP 送達課題
- kl-mutant-io-resistance-combination — 2026-05-23 — KL+KEAP1 IO 抵抗性を metabolic / radiation / IO 内併用で打破する三軸 + lineage plasticity 第四軸
- neoantigen-vaccine-io-clinical-translation — 2026-05-23 — Neoantigen vaccine + IO の HLA 多様性 / clonal selection / mRNA scalability / NSCLC pivotal ladder
- tex-hierarchy-citraconate-rescue — 2026-05-16 — T 細胞疲弊の階層 (Barber 2006 → Im 2016 Tpex → 2026 citraconate) と ICI/CAR-T rejuvenation 統合
- pm2-5-il-1beta-lung-carcinogenesis — 2026-05-16 — PM2.5 → IL-1β → EGFR 変異 NSCLC promotion paradigm の整理 (PM2.5-lung-carcinogenesis concept 同時起票)
- adc-her2-nsclc-paradigm — 2026-05-16 — HER2 変異 NSCLC ADC paradigm (T-DM1 失敗 → T-DXd → DESTINY-Lung04 1L 期待)
- net-targeting-clinical-translation — 2026-05-11 — Neutrophil/NET 標的化 (DNase I / PAD4 / NE / CXCR1-2) の Phase 状況と Risk-benefit
- ev-liquid-biopsy-clinical-implementation — 2026-05-11 — EV liquid biopsy 標準化と CTC/ctDNA に対する付加価値 (exosomal PD-L1 中心)
- brain-metastasis-srs-io-sequencing — 2026-05-11 — 脳転移 SRS/SRT + IO sequencing、RN リスクと CNS-active TKI 選択基準
- sclc-molecular-subtype-treatment-selection — 2026-05-11 — SCLC subtype (A/N/P/I) と DLL3 / Aurora / PARP / IO の予測精度整理
- kras-g12d-druggability-io-resistance — 2026-05-02 — KRAS G12D/G12V druggability と STK11/KEAP1 co-mutation IO 抵抗性克服
- adc-payload-diversity-ild-management — 2026-05-02 — ADC payload 多様化・ILD 管理・cross-resistance の整理
- egfr-osimertinib-post-resistance-strategy — 2026-05-02 — EGFR osimertinib 耐性後の治療戦略 (C797S/MET amp/組織型変化別)
- neutrophil-ev-overview — 2026-05-01 — 好中球由来 EV の分類体系・SEAD 経路・疾患における役割・治療応用
- nets-neutrophil-extracellular-traps-overview — 2026-05-01 — NETs (Neutrophil Extracellular Traps) の包括的解説
- hallmarks-of-cancer-overview — 2026-05-01 — Hallmark of cancer の概念整理 (Hanahan 2000→2011→2022→2026 の進化と Wiki 内実装例)